OncoMatch/Clinical Trials/NCT05199311
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Is NCT05199311 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Carfilzomib and Iberdomide for multiple myeloma.
Treatment: Carfilzomib · Iberdomide · Oral Dexamethasone — This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: iberdomide (iberdomide)
Prior use of iberdomide
Cannot have received: systemic myeloma drug therapy
Exception: within the last 14 days of initiating IP
Use of any systemic myeloma drug therapy within the last 14 days of initiating IP
Cannot have received: investigational agent
Exception: within 28 days or 5 half-lives (whichever is longer) of initiating IP
Subject has been treated with an investigational agent (ie, an agent not commercially available) within 28 days or 5 half-lives (whichever is longer) of initiating IP
Lab requirements
Blood counts
ANC < 1,000/μL; Platelet count < 50,000/μL [excluded]
Kidney function
serious renal impairment (CrCl < 30 mL/min) or requiring dialysis [excluded]
Liver function
SGOT/AST or SGPT/ALT ≥ 2.5 x ULN; serum total bilirubin, direct bilirubin, or alkaline phosphatase ≥ 1.5 x ULN [excluded]
Cardiac function
LVEF < 40% by ECHO [excluded]; active congestive heart failure (NYHA III-IV), symptomatic ischemia, uncontrolled arrhythmias, QTc > 470 msec, pericardial disease, or MI within 4 months prior to randomization [excluded]
ANC < 1,000/μL; Platelet count < 50,000/μL; Corrected serum calcium > 13.5 mg/dL; SGOT/AST or SGPT/ALT ≥ 2.5 x ULN; serum total bilirubin, direct bilirubin, or alkaline phosphatase ≥ 1.5 x ULN; CrCl < 30 mL/min or requiring dialysis; LVEF < 40% by ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Lombardi Comprehensive Cancer Center · Washington D.C., District of Columbia
- John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify